Fig. 1.

Reduction of long-term cognitive and functional decline in AD patients on combination therapy with ChEI and memantine – evidence from a naturalistic LTOC study [31]. a Trajectory of decline predicted over 4 years for groups of patients with AD starting with 10 errors on the Blessed Dementia-Information Memory Concentration scale (BDS; MMSE score of approx. 22) is lowest in the ChEI + memantine combination therapy group. b Trajectory of decline predicted over 4 years for groups of patients with AD starting with 25% dependence on the Weintraub Activities of Daily Living Scale (ADL) is lowest in the combination therapy group.